Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023 Oct;25(10):2950-2959.
doi: 10.1007/s12094-023-03159-9. Epub 2023 Apr 7.

Observational study of HR+/HER2- metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS)

Salvador Blanch  1 , Juan Miguel Gil-Gil  2 , Miriam Arumí  3 , Elena Aguirre  4 , Miguel Ángel Seguí  5 , Manuel Atienza  6 , Silvia Díaz-Cerezo  6 , Alberto Molero  7 , José Manuel Cervera  6 , Joaquín Gavilá  1
Affiliations
Observational Study

Observational study of HR+/HER2- metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS)

Salvador Blanch et al. Clin Transl Oncol. 2023 Oct.

Abstract

Introduction/objectives: To describe abemaciclib use in patients with hormone receptor-positive, human epidermal growth factor receptor-negative (HR+/HER2-) metastatic breast cancer (mBC) who participated in the Named Patient Use program (NPU) in Spain.

Material and methods: This retrospective study was based on medical record review of patients across 20 centers during 2018/2019. Patients were followed up until death, enrolment in a clinical trial, loss of follow-up or study end. Clinical and demographic characteristics, treatment patterns and abemaciclib effectiveness were analyzed; time-to-event and median times were estimated using the Kaplan-Meier (KM) method.

Results: The study included 69 female patients with mBC (mean age 60.4 ± 12.4 years), 86% of whom had an initial diagnosis of early BC and 20% had an ECOG ≥ 2. Median follow-up was 23 months (range 16-28). Metastases were frequently observed in bone (79%) and visceral tissue (65%), with 47% having metastases in > 2 sites. Median number of treatment lines before abemaciclib was 6 (range 1-10). Abemaciclib monotherapy was received by 72% of patients and combination therapy with endocrine therapy by 28% of patients; 54% of patients required dose adjustments, with a median time to first adjustment of 1.8 months. Abemaciclib was discontinued in 86% of patients after a median of 7.7 months (13.2 months for combination therapy and 7.0 months for monotherapy) mainly due to disease progression (69%).

Conclusion: These results suggest that abemaciclib is effective, as monotherapy and in combination, for patients with heavily pretreated mBC, consistent with clinical trial results.

Keywords: Abemaciclib; Effectiveness; HR+/HER2− Spain; Metastatic breast cancer; Real world.

PubMed Disclaimer

Conflict of interest statement

MaA, SD, AM and JMC are employees and shareholders of Eli Lilly and Company. SB, JMGG, MiA, MAS and JG received an economic compensation from Eli Lilly and Co. for their participation in the study (consultancy and/or data collection tasks).

Figures

Fig. 1
Fig. 1
AbemusS study population. mBC metastatic breast cancer, NSAI non-steroidal aromatase inhibitor
Fig. 2
Fig. 2
Progression-free survival according to regimen received (abemaciclib as monotherapy or in combination)
Fig. 3
Fig. 3
Overall survival according to regimen received (abemaciclib as monotherapy or in combination)
Fig. 4
Fig. 4
The AbemusS study design. NPU Named Patient Use Program
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Estimaciones de la incidencia del cáncer en España, 2022. Red Española de Registros de Cáncer (REDECAN) [Internet]. 2022. https://redecan.org/storage/documents/873877e1-af1b-43fe-8d97-0ee1434fe2.... Cited 12 Sept 2022.
    1. Grupo Español de Investigación en cáncer de mama (GEICAM). Guía GEICAM de Práctica Clínica Para el Diagnóstico y Tratamiento del Cáncer de Mama Metastásico GUÍA RESUMIDA 2015 [Internet]. San Sebastián de los Reyes; 2015. http://www.geicam.org. Cited 13 Nov 2021.
    1. Deluche E, Antoine A, Bachelot T, Lardy-Cleaud A, Dieras V, Brain E, et al. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016. Eur J Cancer [Internet]. 2020;129:60–70. doi: 10.1016/j.ejca.2020.01.016. - DOI - PubMed
    1. Başaran GA, Twelves C, Diéras V, Cortés J, Awada A. Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. Cancer Treat Rev [Internet]. 2018;63:144–155. doi: 10.1016/j.ctrv.2017.12.002. - DOI - PubMed
    1. Auguste A, Cortet M, Dabakuyo-Yonli TS, Launay L, Arnould L, Desmoulins I, et al. Breast cancer subtype of French women is not influenced by socioeconomic status: a population-based-study. PLoS ONE [Internet]. 2017;12(2). /pmc/articles/PMC5310911/. Cited 12 Nov 2021. - PMC - PubMed

Publication types